[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"post-acute-covid-19-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:post-acute-covid-19-syndrome":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,23,0,[8,47,60,91,123,149,177,204,230,316,336,361,388,413,449,478,505,533,555,574,604,632,656],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100053555","phase-1-phase-i-open-label-safety-trial-of-pembrolizumab-for-neurological-post--acute-sequelae-of-sars-cov-2-pd1-pasc-i-100053555",false,"NCT07388550","Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)","Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post-Acute Sequelae of SARS-CoV-2 (PD1-PASC I)","* INCLUSION CRITERIA:\n\nTo be eligible to participate in this study, an individual must meet all the following criteria:\n\n* Stated willingness to comply with all study procedures and availability for the duration of the study.\n* Male or female, aged at least 18 or older.\n\n  --Documentation of the SARS-CoV-2 infection that led to development of PASC confirmed either by a positive testing by a commercial laboratory or a positive home test followed by confirmatory nucleocapsid antibody testing.\n* Previously diagnosed with mild-moderate COVID-19 (WHO Clinical Progression Scale between 2-5. Participants who had severe acute COVID-19 requiring hospitalization or ICU care are excluded.\n* If participants had multiple SARS-CoV-2 infections, they would need to be at least 6 months after the last infection.\n* All participants would need to have a negative SARS-CoV-2 nasal swab at the time of enrollment.\n* Exhibiting persistent neurologic symptoms evidenced by a self-reported illness narrative of the development of persistent PASC symptoms after recovering from a SARS-CoV-2 infection. These include symptoms such as fatigue, cognitive difficulties, sleep disturbances, orthostatic intolerance, and any ongoing issues with gait instability, vision, speech, swallowing, sensation, or strength. Symptoms must persist for at least 6 months after the diagnosis of acute COVID-19.\n* All participants will have PD-1 expression on CD8 T cells that is one SD above the mean value of normal controls as established in the SINS Lab and published previously.\n* Moderate to severe PASC symptom severity, as determined using PCFS (minimal score of 3).\n* Ability of participant to understand and sign a written informed consent document.\n* Prior completion of a clinical brain MRI after the diagnosis of COVID-19, or willingness to complete a brain MRI.\n* Agrees not to have vaccinations over the course of the study.\n* Participants of childbearing potential must agree to use a combination of contraception (defined as two forms of effective birth control) or have had surgical sterilization, from the time of enrollment until 4 months after the dose of study drug.\n* Participants capable of sperm donation must agree to not donate sperm from the time of enrollment until 4 months after the dose of study drug.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* For participants who have not completed a brain MRI since onset of symptoms: inability to complete brain MRI with gadolinium including contraindicated metal in the body, prior allergic reaction to gadolinium, eGFR \\\u003C45 mmol\u002FL, or claustrophobia that is unable to be adequately treated with a low dose oral benzodiazepine.\n* Contraindication to a research lumbar puncture, including use of anticoagulant medication, platelets \\\u003C 50,000\u002FuL, PT or PTT \\>1.5 x ULN for the NIH Clinical Center, if risk of lumbar puncture is increased for other reasons such as space occupying lesion, skin infection at site of the puncture or otherwise inability to complete the procedure.\n* A condition that would significantly confound interpretation of the clinical and research tests as determined by the study investigators. This could include traumatic brain injury, substance use disorder, active malignancy, systemic immunologic disorders, current or previous long-term immune suppressive therapy.\n* Any premorbid medical condition that would potentially cause fatigue and exercise intolerance. This includes many chronic medical diseases, such as congestive heart failure, coronary artery disease, chronic obstructive pulmonary disease, severe arthritis, uncontrolled asthma, renal failure, fibromyalgia, and ME\u002FCFS.\n* Symptom severity that makes it impossible for the participant to travel to NIH.\n* Received a SARS-CoV-2 vaccine dose within less than 4 weeks of enrollment or is planning for any additional vaccines during the study.\n* Prior treatment for PASC with immunomodulatory therapies such as check point inhibitors which in the opinion of the investigators could impact the outcome of this study.\n* Current medications include oral steroids or other immunosuppressive medications which in the opinion of the investigators could impact the outcome of this study.\n* Active participation in a clinical protocol which includes any intervention that may affect the results of the current study.\n* Abnormal anti-thyroid panel (anti-TPO and anti-TG) test at screening visit.\n* ANA titer of 1:80 or greater, positive anti-CCP.\n* Abnormal screening blood tests exceeding any of the limits defined below or as deemed exclusionary by the investigators on review at baseline:\n\n  * Aspartate aminotransferase and alanine aminotransferase values \\>2x upper limit of normal precluding the use of acetaminophen\n  * Fasting triglyceride \\> 300 mg\u002FdL.\n  * Total bilirubin \\>2x upper limit of normal (unless participant has Gilbert syndrome)\n  * Creatinine Clearance or eGFR \\\u003C60 ml\u002Fminute (adjusted for race)\n  * Hemoglobin \\\u003C 10 g\u002FdL\n  * Absolute neutrophil count \\\u003C 1000\u002Fmicroliter\n  * Platelet count \\\u003C130,000\u002Fmm3 (if platelet clumping is present on hematology slide review, platelet count \\\u003C100,000\u002Fmm3 is considered exclusionary to study)\n  * Hemoglobin A1c \\>= 6%\n  * Thyroid-stimulating hormone (TSH) and adrenocorticotropic hormone (ACTH) within normal limits. If TSH is not within normal limits then the participant may be eligible if thyroxine (T4) is within normal limits. Participants are not excluded if they are on a stable dose of replacement thyroid medication; dose may be adjusted as needed.\n* Previously documented anaphylaxis or severe systemic reaction to check point inhibitors, acetaminophen, or diphenhydramine.\n* A severe psychiatric condition, which based on the assessment of the study investigators, will impact the ability to complete the study.\n* Pregnancy or planning to get pregnant.\n* Currently lactating\u002Fbreastfeeding.\n* Current or previous malignancy. A history of malignancy that has fully resolved with surgical resection only (e.g. no chemotherapy, radiation therapy, or immunotherapy) will be allowed.\n* Current or past substance use disorder within last five years. Marijuana use within the past five years will not be an exclusion.\n* Infection with HIV, tuberculosis, hepatitis B or C.","ALL","18 Years","110 Years",{"count":20,"type":21},15,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","Background:\n\nSARS-CoV-2 is the virus that causes COVID-19. Some people who recover from an acute COVID-19 infection may continue to have symptoms that persist for months or years. These can include neurological symptoms, such as headaches, loss of taste or smell, dizziness, or trouble walking. Pembrolizumab is a drug approved to treat certain cancers. Researchers think this drug might reduce long-term neurologic symptoms after a COVID-19 infection.\n\nObjective:\n\nTo test pembrolizumab in people with ongoing neurologic symptoms of COVID-19.\n\nEligibility:\n\nPeople aged 18 years or older who had COVID-19 at least 6 months ago and have ongoing neurologic symptoms.\n\nDesign:\n\nParticipants will have 7 clinic visits in 7 months.\n\nParticipants will be screened. They will have a physical exam with blood tests. Swabs will be used to collect cells from inside the mouth and nose. They may opt to have an imaging scan.\n\nParticipants will also have other tests before they are given the study drug. These include eye and skin exams; tests of their memory and thinking; and tests of involuntary body functions, such as heart rate, blood pressure, sweating, and digestion. Their grip strength and walking pace will be measured. They will wear a heart rate monitor for 24 hours. They will wear devices on a wrist and thigh to measure activity for 10 days.\n\nParticipants will have a lumbar puncture (spinal tap): A thin needle will be inserted into their lower back to draw out a sample of the fluid around their spinal cord.\n\nPembrolizumab is given through a needle inserted into a vein. Participants will receive 1 dose of the drug.\n\nParticipants will have 4 follow-up visits over 6 months. Tests may be repeated during these visits.",[27],"Post-Acute COVID-19 Syndrome",[29,30,31,32,33],"PASC","Long Covid","COVID","COVID-19","Postacute Sequelae of COVID","NOT_YET_RECRUITING","2026-07-10",{"date":37,"type":38},"2026-07-13","ACTUAL",{"date":40,"type":21},"2026-07-16",{"date":42,"type":21},"2028-01-01",{"name":44,"class":45},"National Institute of Neurological Disorders and Stroke (NINDS)","NIH",1,{"id":48,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":50,"briefSummary":25,"conditions":51,"keywords":52,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":59,"locationsCount":46},"100622817",{"count":20,"type":21},[24],[27],[29,30,31,32,33],"2026-07-01",{"date":55,"type":38},"2026-07-02",{"date":57,"type":21},"2026-07-07",{"date":42,"type":21},{"name":44,"class":45},{"id":61,"slug":62,"hasResults":11,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":11,"sex":16,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":4,"studyType":22,"phases":72,"briefSummary":74,"conditions":75,"keywords":77,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":46},"100514337","dietary-intervention-to-mitigate-post-acute-covid-19-syndrome-100514337","NCT05977179","Dietary Intervention to Mitigate Post-Acute COVID-19 Syndrome","A Diet Intervention Study To Mitigate Fatigue Symptoms And To Improve Muscle And Physical Function In Older Adults With Post-Acute COVID-19 Syndrome","Long-COVIDiet","Inclusion Criteria:\n\n1. Age of 50 years or older\n2. No known active infectious disease (COVID-19 or other).\n3. Participant diagnosed with long-COVID\u002F post- acute COVID-19 syndrome (PACS) \u002FICD-10-CM codes U09.9\n4. Moderate\u002Fsevere fatigue Brief Fatigue Inventory (BFI)≥4\n5. Poor diet quality assessed by the short Healthy Eating Index (HEI)\\\u003C70\n\nExclusion Criteria:\n\n1. Participants with a home oxygen requirement or requiring chronic ventilator support\n2. Participants diagnosed with diabetes who do not have a recent HbA1c level or with HbA1c \\> 9%\n3. Participants diagnosed with Congestive Heart Failure (CHF New York Heart Association) \\> class 2\n4. Participants with dietary restrictions due to medication use that affects blood clotting, such as Warfarin or other reasons.\n5. Evidence of any condition as determined by a physician or the study team that would lead to an increased risk of illness due to any aspect of proposed testing and interventions, or introduce unanticipated confounding of study results.\n6. Participants diagnosed with uncontrolled hypertension that will be defined as:\n\n   1. Systolic blood pressure consistently equal to or higher than 190 mmHg.\n   2. Diastolic blood pressure consistently equal to or higher than 110 mmHg.\n   3. Participants with a recent history of hypertensive crisis (severe elevation in blood pressure requiring immediate medical intervention), regardless of current blood pressure levels.\n7. Participants with diet restrictions or allergies that can affect adherence to the diet, such as allergy to fish or shellfish.\n8. Participation in another trial in which active intervention is being received.\n9. Participants with active drug or alcohol use\u002Fdependence that would interfere with adherence to the study.\n10. Participants scheduled for surgical procedures within the next 6 months.\n11. Participants diagnosed with active cancer.\n12. Participants diagnosed with liver diseases.\n13. Participants diagnosed with kidney-related conditions, including Chronic Kidney Disease (CKD) \\> stage 3.\n14. Below the age of 50 years.","50 Years","94 Years",{"count":71,"type":21},56,[73],"NA","The primary objective of this study is to conduct a 16-week randomized controlled trial aimed at investigating the effectiveness of the Whole-Diet Approach when following a healthy US-style diet rich in anti-inflammatory properties. The study will focus on evaluating its impact on reducing symptoms related to Post-Acute Sequelae of SARS-CoV-2 Infection (PACS) in adults aged 50 years and older.\n\nThe main research questions this study aims to answer are:\n\n1. Does adhering to a healthy US-style diet, which is abundant in anti-inflammatory properties, effectively mitigate fatigue symptoms in adults with PACS?\n2. Does adhering to a healthy US-style diet, which is abundant in anti-inflammatory properties, effectively mitigate declines in muscle function and physical performance in adults with PACS?\n\nAt the beginning of the study, eligible participants will be randomly assigned to either the Dietary Intervention Group, where they will receive personalized dietary plans and weekly sessions, or the Attention Control Group, where they will attend general health sessions on a weekly basis as well.\n\nThis research intends to shed light on the potential benefits of the Whole-Diet Approach and its role in ameliorating PACS-related symptoms among older adults. By comparing the outcomes of the two groups, we hope to gain valuable insights into the effectiveness of this dietary intervention in improving the quality of life for individuals dealing with PACS.",[27,76],"Fatigue",[31,78,79],"long-COVID","DIET","RECRUITING","2026-06-19",{"date":83,"type":38},"2026-06-23",{"date":85,"type":38},"2025-05-12",{"date":87,"type":21},"2028-09-30",{"name":89,"class":90},"University of Maryland, Baltimore","OTHER",{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":99,"enrollmentInfo":100,"targetDuration":4,"studyType":22,"phases":102,"briefSummary":103,"conditions":104,"keywords":106,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":46},"100640470","diaphragmatic-breathing-exercises-with-kots-currents-in-patients-with-long-covid-100640470","NCT07621588","Diaphragmatic Breathing Exercises With KOTS Currents in Patients With Long COVID","Effects of Diaphragmatic Breathing Exercises Combined With Diaphragmatic Electrostimulation Using KOTS Currents in Patients With Long COVID: A Pilot Randomized Controlled Trial","KOTS-LC","Inclusion Criteria:\n\n* Men and women aged 18 to 65 years.\n* Medical diagnosis of Long COVID.\n* At least 2 months since SARS-CoV-2 infection.\n* Ability and willingness to provide informed consent.\n* Ability to participate in the assigned intervention and assessment procedures.\n\nExclusion Criteria:\n\n* Presence of a pacemaker.\n* History of epilepsy.\n* Pregnancy.\n* History of acute cardiac arrest.\n* Severe respiratory distress.\n* Use of a wheelchair.\n* Blurred vision.\n* Cyanosis.\n* Refusal to perform part or all of the treatment.\n* Incomplete or incorrectly completed questionnaires.","65 Years",{"count":101,"type":21},10,[73],"This study will evaluate the effects of diaphragmatic breathing exercises combined with diaphragmatic electrostimulation using KOTS currents in patients with Long COVID. Participants will be randomly assigned to one of two groups. The control group will perform diaphragmatic breathing exercises, while the intervention group will perform diaphragmatic breathing exercises combined with diaphragmatic electrostimulation using KOTS currents. The intervention will last three weeks, with two sessions per week. The study will assess respiratory function, quality of life, physical function, dyspnea, fatigue, and basal oxygen saturation.",[105,27],"Long COVID Syndrome",[107,108,109,110,111,112,113],"Diaphragmatic Breathing","KOTS Currents","Russian Currents","Diaphragmatic Electrostimulation","Quality of Life","Respiratory Rehabilitation","Spirometry","2026-06-02",{"date":116,"type":38},"2026-06-04",{"date":118,"type":21},"2026-06",{"date":120,"type":21},"2026-07",{"name":122,"class":90},"Universidad Pontificia de Salamanca",{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":131,"targetDuration":4,"studyType":22,"phases":133,"briefSummary":134,"conditions":135,"keywords":136,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":46},"100609550","harnessing-optimism-and-perseverance-in-the-face-of-long-covid-espaol-100609550","NCT07216040","Harnessing Optimism and Perseverance in the Face of Long COVID-Español","Harnessing Optimism and Perseverance in the Face of Long COVID~Español (HOPE-LC~Español)","HOPE-LC","Inclusion Criteria:\n\n* Age 18 years or older.\n* Speaks and understands Spanish at a level that allows active participation in group-based study procedures.\n* Self-reported history of Long COVID\u002Fpost-COVID condition of any severity or duration, including ongoing emotional or cognitive symptoms affecting daily functioning or a medical professional has diagnosed you with a Long COVID\u002Fpost-COVID condition of any severity or duration, including ongoing emotional or cognitive symptoms.\n* Ability to participate in group sessions either in-person or via telehealth (Zoom).\n* Willingness and capacity to provide informed consent.\n\nExclusion Criteria:\n\n* Presence of severe psychiatric conditions that would preclude participation in group therapy (e.g., active psychosis, suicidal intent requiring immediate intervention).\n* Inability to communicate in Spanish sufficiently to engage meaningfully in group sessions.\n* Cognitive or physical impairments prevent participation in group sessions or completion of surveys, without available accommodations.\n* Concurrent participation in another conflicting interventional trial targeting Long COVID symptoms.",{"count":132,"type":21},25,[73],"The Harnessing Optimism and Perseverance in the Face of Long COVID (HOPE-LC) program, created by Drs. Eric Watson and Amelia Hicks, is a group therapy model designed to foster resilience, adjustment, and coping skills for those living with chronic Long COVID. HOPE-LC\\~Español provides a culturally and linguistically adapted version for Spanish-speaking individuals in Queens, developed with input from Spanish-speaking clinicians, Long COVID experts, and people with lived experience. Partnering with H+H\u002FElmhurst and H+H\u002FQueens, the project aims to recruit 25 participants and evaluate program feasibility and preliminary efficacy.",[27],[27,137,138,139],"group therapy","acceptance and commitment therapy","Spanish-speaking","2026-04-20",{"date":142,"type":38},"2026-04-23",{"date":144,"type":21},"2026-05",{"date":146,"type":21},"2026-08-31",{"name":148,"class":90},"Icahn School of Medicine at Mount Sinai",{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":156,"targetDuration":4,"studyType":22,"phases":158,"briefSummary":159,"conditions":160,"keywords":165,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":46},"100523408","long-covid-brain-fog-cognitive-rehabilitation-trial-100523408","NCT06095297","Long COVID Brain Fog: Cognitive Rehabilitation Trial","Technique to Enable Return-to-Work by Employees With Long COVID Brain Fog","Inclusion Criteria:\n\n* \\>3 months post COVID\n* mild or greater cognitive impairment\n* moderate or greater brain fog\n* impairment in performance of daily activities\n* reside in community\n* reliable transportation to lab\n* sufficiently mentally and physically fit\n* adequate sight and hearing\n* ability to follow directions, and retain information\n* sufficient English proficiency\n\nExclusion Criteria:\n\n* cognitive impairment due to developmental disability, psychiatric disorder, or substance abuse, TBI or progressive brain disease\n* stroke prior to the onset of COVID\n* current substance abuse disorder\n* prior cognitive processing speed training on DoubleDecision or similar program\n* cannot tolerate trans-auricular vagus nerve stimulation",{"count":157,"type":21},30,[73],"This study will compare two approaches to cognitive rehabilitation in adults with long COVID with persistent, mild to moderate, cognitive impairment. One approach will feature (A) web-based computer \"games\" that trains how quickly individuals process information that they receive through their senses; (B) in-lab training on everyday activities with important cognitive components, (C) procedures designed to transfer improvements in cognition from the treatment setting to everyday life, and (D) a non-invasive form of vagus nerve stimulation (VNS), i.e., trans-auricular VNS (taVNS). Component B will include work-related tasks. This approach is termed Constraint-Induced Cognitive Therapy (CICT). The other approach will feature (A) web-based computer \"games\" that train reaction time and eye-hand coordination; (B) in-lab training on relaxation, healthy nutrition, and healthy sleep, (C) procedures designed to promote integration of these lifestyle changes into everyday life, and (D) taVNS. This approach is termed Brain Fitness Training (BFT).\n\nA subset of participants, who qualify for and and desire vocational rehabilitation (VR), will receive VR from the Alabama Department of Rehabilitation Services (ADRS) in addition to CICT or BFT. ADRS VR will include career counseling, prescription of on-the-job accommodations, and guidance on return-to-work. Those in the CICT + VR group will also receive on-the-job coaching from a peer mentor for a month after completing training.\n\nCICT, with or without VR, will involve 30 hours of training. Ten 3-hour in-lab, face-to-face, therapist-directed sessions will be scheduled. These sessions will feature one hour of gaming; the remainder will be committed to in-lab training on the target behaviors and the procedures designed to promote transfer of therapeutic gains to daily life and improving skills essential to work; the set of the latter procedures is termed the Transfer Package. ta-VNS will administered for 10 minutes before gaming and in-lab target behavior training. To accommodate the demands of participants' other activities, training sessions will be permitted to be scheduled as tightly as every weekday over 2 weeks or as loosely as every other weekday or so over 4 weeks. If a family caregiver is available, they will receive training on how to best support participants in their therapeutic program. After training ends, four follow-up phone calls will be scheduled approximately one-week apart with participants to promote integration of the skills gained during training into everyday life.\n\nBFT, with or without VR, will involve 30 hours of training following the same schedule as for CICT. Ten 3-hour in-lab, face-to-face, therapist-directed sessions will be scheduled. These sessions will feature one hour of gaming; the remainder will be committed to in-lab training on the target behaviors (healthy sleep, nutrition and relaxation habits) and the procedures designed to promote transfer of behavior change to daily life. ta-VNS will be administered for 10 minutes before gaming and in-lab target behavior training. If a family caregiver is available, they will receive training on how to best support participants in their therapeutic program. After training ends, four follow-up phone calls will be scheduled approximately one-week apart with participants to promote integration of the skills gained during training into everyday life.\n\nParticipants will be randomly assigned to the interventions. Randomization will be stratified by whether participants qualify for and desire VR from ADRS or not. If yes, participants will be randomized in equal numbers to CICT + VR or BFT + VR. If no, participants will be randomized in equal numbers to CICT or BFT.\n\nTesting will happen one month before treatment, one day before treatment, one day afterwards, and 6-months afterwards. Outcomes measured will include cognitive processing speed, cognitive function on laboratory tests, and spontaneous performance of everyday activities with important cognitive components in daily life. Another important outcome measure will be whether or not participants were able to return back to work or had significant improvements in their work activities.",[161,162,163,164,27],"Long COVID","Brain Fog","Cognitive Impairment","Cognitive Dysfunction",[161,162,163,166,32,29,167],"Vocational Rehabilitation","Cognitive Rehabilitation","2026-04-06",{"date":170,"type":38},"2026-04-13",{"date":172,"type":38},"2024-04-25",{"date":174,"type":21},"2027-12",{"name":176,"class":90},"University of Alabama at Birmingham",{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":183,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":185,"targetDuration":4,"studyType":22,"phases":187,"briefSummary":188,"conditions":189,"keywords":190,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":46},"100528994","exercise-training-using-an-app-on-physical-cardiovascular-function-individuals-with-post-covid-19-syndrome-100528994","NCT06168006","Exercise Training Using an App on Physical Cardiovascular Function Individuals With Post-covid-19 Syndrome","Effects of a Physical Training Program Using a Mobile App on the Functionality and Cardiovascular Function of Individuals With Post-covid-19 Syndrome: Randomized Clinical Trial","Recovery","Inclusion Criteria:\n\n* Laboratory diagnosis of COVID-19\n* Fatigue ≥ 8 points on the Chalder Scale and\u002For dyspnea 2-4 on the Modified Medical Research Council\n* Have access to a smartphone\n* Have no contraindications for exercise practice\n* Have ability to sit and stand and maintain balance while standing\n* Have preserved cognitive function\n* Have no risk of falls according to the Morse Fall Scale",{"count":186,"type":21},60,[73],"The aim of this study is to assess the effect of a physical exercise program via a mobile application on functional parameters in individuals with post-COVID-19 syndrome. This is a clinical trial involving 60 individuals with post-COVID syndrome who will be randomly assigned to either a control group (physical activity guideline) or an experimental group (app-based training).",[27],[191,192,193,194],"exercise","mobile app","physical function","cardiovascular function","2026-02-16",{"date":197,"type":38},"2026-02-17",{"date":199,"type":38},"2024-03-01",{"date":201,"type":21},"2026-06-30",{"name":203,"class":90},"University of Nove de Julho",{"id":205,"slug":206,"hasResults":11,"nctId":207,"briefTitle":208,"officialTitle":209,"acronym":4,"eligibilityCriteria":210,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":211,"targetDuration":4,"studyType":22,"phases":213,"briefSummary":215,"conditions":216,"keywords":220,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":46},"100607544","phase-2-effect-of-2-hoba-in-persistent-immune-activation-in-long-covid-pots-100607544","NCT07189936","Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS","Mechanism of Isolevuglandin-Protein Adduct Formation in Persistent Immune Activation in Long COVID POTS","Inclusion Criteria:\n\nAll participants should meet diagnostic criteria for Long COVID and POTS and as outlined below:\n\nLong COVID (LC) is defined by a range of symptoms affecting multiple organs that persist for more than three months following an acute SARS-CoV-2 infection.\n\nPOTS: the presence of chronic symptoms lasting more than 3 months, along with orthostatic tachycardia (a HR increase over 30 bpm upon standing or exceeding 120 bpm without orthostatic hypotension) within 10 minutes upon standing or 75-degree head up tilt.\n\nFor patients aged 18 and 21, an increase of more than 40 bpm or a standing HR over 130 bpm will be required for inclusion in the study.\n\n2 Patients need confirmation of POTS diagnosis based on orthostatic vital signs obtained prior to enrollment in the study.\n\nSARS-CoV-2 infection 3 or more months prior identified by the follow signs:\n\nA. Meets the clinical OR epidemiological criteria.\n\n1. Clinical criteria: Acute onset of fever AND cough (influenza-like illness) OR Acute onset of ANY THREE OR MORE of the following signs or symptoms: fever, cough, general, weakness\u002Ffatigue, headache, myalgia, sore throat, coryza, dyspnea, nausea, diarrhea, anorexia.\n2. Epidemiological criteria: Contact of a probable or confirmed case or linked to a COVID-19 cluster; or B. Presents with acute respiratory infection with history of fever or measured fever of ≥ 38°C; and cough; with onset within the last 10 days; and who requires hospitalization); or C. Presents with no clinical signs or symptoms, NOR meeting epidemiologic criteria with a positive professional use or self-test SARS-CoV-2 antigen-Rapid Diagnostic Test.\n\nD. A person with a positive nucleic acid amplification test, regardless of clinical criteria OR epidemiological criteria; or E. Meeting clinical criteria AND\u002FOR epidemiological criteria (See A). With a positive professional use or self-test, SARS-CoV-2 Antigen-Rapid Diagnostic Test.\n\nF. Documented by health care provider in clinical note or encounter.\n\nExclusion Criteria:\n\n1. Known active acute SARS-Cov-2 infection (4 weeks from onset)\n2. Moderate or severe immunocompromised patients,\n3. Known history of cardiovascular disease (atrioventricular block (AV block), myocardial infarction, angina, heart failure, pacemaker, stroke, transient ischemic attack within 6 months before enrollment),\n4. Uncontrolled hypertension (BP\\>140\u002F90 despite appropriate treatment);\n5. Type 1 or type 2 diabetes mellitus;\n6. Impaired hepatic function (AST or ALT greater than 1.5x the upper limit of normal or with total bilirubin ≥1.5mg\u002Fdl),\n7. Impaired renal function test (eGFR\\\u003C60 mL\u002Fmin\u002F1.73m2),\n8. Anemia (hemoglobin \\\u003C10 g\u002Fdl),\n9. Pregnant or breastfeeding women,\n10. Known history of autoimmune disease, steroid use or other immunotherapies,\n11. Inability to provide informed consent.\n\nWe will also exclude individuals with known allergy sensitivity to components of the study medication, known contraindication to the study interventions, use of central acetylcholinesterase inhibitors (e.g., pyridostigmine, donezepil), aspirin allergy because salicylic acid is a metabolite of 2-HOBA; use of monoamine oxidase inhibitors (MAO-I) because of some inhibition of MAO-A is present in the anticipated therapeutic range of 2-HOBA.\n\n\\-",{"count":212,"type":21},50,[214],"PHASE2","Long COVID is defined by a range of symptoms affecting multiple organs that persist for more than three months following an acute SARS-CoV-2 infection. Approximately 7% of individuals who recover from SARS-Cov-2 infection develop Long COVID.\n\nLong COVID Postural Orthostatic Tachycardia Syndrome (LCPOTS) symptoms include fatigue, exercise intolerance, orthostatic intolerance, syncope, and heightened orthostatic tachycardia.\n\nResearch has found that decreased parasympathetic activity in LCPOTS increases the production of highly immunogenic neoantigens Isolevuglandins (IsoLG-adducts). IsoLG-adducts induce formation of circulating monocyte\u002FT cell complexes(doublets) leading to the persistent and unresolved immune response that continues after the initial infection.\n\nThe purpose of the this research, is to study the effects of 2-hydroxybenzylamine (2-HOBA), an Iso-LG-adduct scavenger, its effects in immune markers and compare it with Placebo",[27,217,218,219],"Postural Tachycardia Syndrome (POTS)","SARS CoV 2 Infection","Long COVID19",[161],"2026-01-21",{"date":223,"type":38},"2026-01-22",{"date":225,"type":38},"2025-12-18",{"date":227,"type":21},"2029-06-30",{"name":229,"class":90},"Vanderbilt University Medical Center",{"id":231,"slug":232,"hasResults":11,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":4,"eligibilityCriteria":236,"healthyVolunteers":237,"sex":16,"minAge":238,"maxAge":4,"enrollmentInfo":239,"targetDuration":241,"studyType":242,"phases":4,"briefSummary":243,"conditions":244,"keywords":287,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":309,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":46},"100424417","unhide-project-a-digital-health-platform-to-collect-lifestyle-data-for-brain-inflammation-research-100424417","NCT04806620","Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research","Unhide® Project Also Known as The Unhide® Solve Together Unified Platform","Participants may be either self-diagnosed, or diagnosed by a physician with the following conditions:\n\n* Infection-associated chronic conditions such as Long COVID, chronic Lyme, myalgic encephalomyelitis (ME\u002FCFS), and post-acute neuropsychiatric syndrome (PANS\u002FPANDAS).\n* Neuroimmune, developmental, autonomic, and neurological conditions like migraines, dysautonomia, POTS, multiple sclerosis, and autism spectrum disorder.\n* Autoimmune diseases such as Lupus, Sjogren's Disease, rheumatoid arthritis, myasthenia gravis, ankylosing spondylitis, and related autoimmune conditions.\n\nInflammatory gastrointestinal conditions such as Crohn's Disease, Celiac Disease, and ulcerative colitis.\n\n* Behavioral and mood disorders such as anxiety, depression, bipolar disorder, PTSD, eating disorders, OCD, and other related conditions.\n* \"Healthy\" people (without brain inflammation), including unaffected individuals, unaffected individuals in the same household, and unaffected individuals who are married to relatives and family members.\n* Have consistent internet access and a cell phone, tablet, or PC since this is an online or app-based platform that requires entering data and completing surveys.\n* Currently live in the United States\n* Be able to participate in English (stay tuned for updates about the Spanish language version)\n* Be willing to share symptom and health data through the platform",true,"2 Years",{"count":240,"type":21},10000,"10 Years","OBSERVATIONAL","The unhide® Project is a non-interventional, longitudinal research study designed to establish a secure data repository of demographic, health, and lifestyle information from individuals with brain inflammation and related neuroinflammatory conditions. Participants in the United States aged 2 years and older will provide self-reported health data, biometrics, and symptom diaries through the MyDataHelps™ app (branded as unhide® for this study). The goal is to create comprehensive longitudinal profiles to facilitate research into disease subtypes, causes, diagnostics, and potential treatments, as well as to identify potential participants for future optional studies. \"Healthy\" individuals without brain inflammation are also eligible to participate.\n\nThe digital health research platform used in this study was originally developed and designed by Solve M.E and was called SolveTogether. The Brain Inflammation Collaborative (BIC) expanded upon Solve M.E.'s work to include related diagnoses, pediatric participants, enhance symptom tracking, and more. BIC and Solve M.E. combined Solve Together and unhide®, to create The unhide® Solve Together Unified Platform in 2025.",[27,245,246,247,248,249,250,251,252,253,254,255,256,257,258,259,260,261,262,263,161,264,265,266,267,268,269,270,271,272,273,274,275,276,277,278,279,280,281,282,283,284,285,286],"ME\u002FCFS","Rheumatic Arthritis","Juvenile Rheumatoid Arthritis (JRA)","Psoriatic Arthritis (PsA)","Ankylosing Spondylitis (AS)","Autoimmune Encephalitis","Celiac Disease","Celiac Disease in Children","Chronic Lyme Disease","Post-treatment Lyme Disease Syndrome","Crohn's Disease","Dysautonomia","Anorexia Nervosa","Bulimia Nervosa","ARFID","Avoidant \u002F Restrictive Food Intake Disorder","Ehlers Danlos Syndrome","Endometriosis","Fibromyalgia (FM)","Lupus","Migraines","Mast Cell Activation Syndrome","Multiple Sclerosis","Myalgic Encephalomyelitis (ME)","Myasthenia Gravis, Generalized","Myasthenia Gravis in Children","Narcolepsy","Obsessive Compulsive Disorder (OCD)","PANDAS","Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)","POTS - Postural Orthostatic Tachycardia Syndrome","General Anxiety Disorder, Social Anxiety Disorder","PTSD - Post Traumatic Stress Disorder","Psoriasis","Traumatic Brain Injury","Tourette's Syndrome","Inflammatory Bowel Disease (IBD)","Autoimmune Diseases","Neurological Diseases or Conditions","Psychiatric Disorder","Sjogren's Syndrome","Ulcerative Colitis and Crohn's Disease",[161,288,289,290,291,292,293,294,295,296,245,297,298,299,300,301,265,302,303,304,305,76,306,162,307],"Myalgic Encephalomyelitis","Chronic Fatigue Syndrome","Longitudinal Natural History Study","Observational","Neuroinflammatory Disease","Brain inflammation","Neuroinflammatory disorders","PANS\u002FPANDAS","Autoimmune encephalitis","Dysautonomia \u002F POTS","Multiple sclerosis","Autoimmune disease","Inflammatory bowel disease (Crohn's, ulcerative colitis)","Celiac disease","Mood disorders (anxiety, depression, bipolar, PTSD, OCD)","Mobile health app","Patient registry","Wearable devices","Post-exertional malaise","Mental health","2026-01-20",{"date":223,"type":38},{"date":311,"type":38},"2023-07-05",{"date":313,"type":21},"2030-12-31",{"name":315,"class":90},"Brain Inflammation Collaborative",{"id":317,"slug":318,"hasResults":11,"nctId":319,"briefTitle":320,"officialTitle":320,"acronym":4,"eligibilityCriteria":321,"healthyVolunteers":237,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":322,"targetDuration":4,"studyType":22,"phases":323,"briefSummary":324,"conditions":325,"keywords":327,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":329,"lastUpdatePostDateStruct":330,"startDateStruct":331,"completionDateStruct":333,"leadSponsor":335,"locationsCount":46},"100471617","cardiovascular-autonomic-and-immune-mechanism-of-post-covid-19-tachycardia-syndrome-100471617","NCT05421208","Cardiovascular Autonomic and Immune Mechanism of Post COVID-19 Tachycardia Syndrome","Inclusion Criteria:\n\n* Prior RT-PCR-confirmed COVID-19 infection.\n* Post-COVID-19 POTS will be defined as the presence of orthostatic tachycardia (\\>30 bpm) and chronic (\\>3 months) pre-syncopal symptoms.\n\nExclusion criteria:\n\n* Heart Disease: Myocardial Infarction, angina, heart failure\n* History of stroke, or transient ischemic attack\n* Undergone an invasive procedure for CVD (coronary artery bypass graft, angioplasty, valve replacement, pacemaker placement or other vascular surgeries)\n* Uncontrolled hypertension defined as persistent blood pressure \\>140\u002F90.\n* Post-menopausal women.\n* Diabetes Mellitus Type 1 or Type 2. ,\n* Impaired Hepatic function\n* Impaired renal function test (eGFR\\\u003C60 mL\u002Fmin\u002F1.73m2).\n* Ongoing substance abuse.\n* Mental conditions rendering a subject unable to understand the nature, scope and possible consequences of the study.\n* History of seizures.\n* Chronic use of steroids, NSAIDs.\n* On biologics such as anti-IL6 (omalizumab) and anti-TNF-alpha drugs\n* Pregnancy or breastfeeding",{"count":186,"type":21},[73],"The term post-acute COVID-19 syndrome or Long COVID is a disabling syndrome that persists beyond the 3-month convalescence period after COVID-19 infections.\n\nThis syndrome affects mostly women (\\~80%), present with chronic tachycardia and Orthostatic intolerance symptoms without any identifiable cause. In addition, non-specific symptoms such as fatigue, headache, and \"brain fog\", commonly described in POTS patients are also present in this novel condition, recently named post-COVID-19 tachycardia syndrome, POTS variant.\n\nReduced Vagal activity and unresolved inflammation is post-COVID-19 POTS is hypothesized as the cause of Long COVID",[326,217,161,218],"Post-acute COVID-19 Syndrome",[328],"SARS-CoV-2 infection","2026-01-15",{"date":308,"type":38},{"date":332,"type":38},"2022-06-01",{"date":334,"type":21},"2027-06-30",{"name":229,"class":90},{"id":337,"slug":338,"hasResults":11,"nctId":339,"briefTitle":340,"officialTitle":340,"acronym":341,"eligibilityCriteria":342,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":343,"targetDuration":4,"studyType":242,"phases":4,"briefSummary":345,"conditions":346,"keywords":347,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":353,"lastUpdatePostDateStruct":354,"startDateStruct":355,"completionDateStruct":357,"leadSponsor":358,"locationsCount":360},"100620357","second-prospective-cohort-of-patients-entering-the-multidisciplinary-care-pathway-for-post-covid-syndromes---sypoco2-cohort-100620357","NCT07356570","Second Prospective Cohort of Patients Entering the Multidisciplinary Care Pathway for Post-Covid Syndromes - SyPoCo2 Cohort","SYPOCO 2","Inclusion Criteria:\n\n* Documented SARS-CoV-2 infection\n* Persistent or complex post-COVID symptoms lasting more than 4 weeks or more than 3 months\n* Patient referred to the EPSILON pathway or to the post-COVID rehabilitation unit\n* Age ≥ 18 years\n* Non-institutionalized\n* Expected survival greater than 6 months\n\nExclusion Criteria:\n\n* Refusal to participate or to share data\n* Uncontrolled comorbidities\n* Pregnant or breastfeeding women\n* Persons under legal protection or deprived of liberty\n* Not affiliated with the French national health insurance system",{"count":344,"type":21},150,"The study aims to identify clinical profiles of long-COVID patients and correlate them with immunological and molecular data in order to identify prognostic biomarkers and potential therapeutic targets.",[27],[161,348,349,350,351,352],"SARS-CoV-2","Post-COVID syndrome","Immune response","Biomarkers","Prospective cohort","2026-01-14",{"date":221,"type":38},{"date":356,"type":38},"2025-06-13",{"date":118,"type":21},{"name":359,"class":90},"Hospices Civils de Lyon",2,{"id":362,"slug":363,"hasResults":11,"nctId":364,"briefTitle":365,"officialTitle":366,"acronym":367,"eligibilityCriteria":368,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":369,"targetDuration":4,"studyType":22,"phases":371,"briefSummary":373,"conditions":374,"keywords":376,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":378,"lastUpdatePostDateStruct":379,"startDateStruct":381,"completionDateStruct":383,"leadSponsor":385,"locationsCount":387},"100510443","phase-2-safety-and-efficacy-of-anakinra-treatment-for-patients-with-post-acute-covid-syndrome-100510443","NCT05926505","Safety and Efficacy of Anakinra Treatment for Patients With Post Acute Covid Syndrome","Safety and Efficacy of Anakinra Treatment for Patients With Persistent Respiratory Symptoms Post Acute Covid and Immune System Activation: the Precision Double-blind, Randomized Clinical Trial","PRECISION","Inclusion Criteria:\n\n1. Age equal to or above 18 years\n2. Male or female gender\n3. In the case of women of childbearing age and men, an adequate method of contraception should be used during the study. Contraception should be maintained for at least a period of 3 months after the discontinuation of treatment. As an adequate method of contraception, it is suggested: -male or female condom with or without spermicide -contraceptive cap, a diaphragm or contraceptive sponge with a spermicide Prior to admission to the study, a pregnancy test will be performed to exclude pregnancy to women of childbearing age.\n4. Written informed consent provided by the patient. For subjects without decision-making capacity, informed consent must be obtained from a legally designated representative following the national legislation in the Member State where the trial is planned.\n5. History of confirmed COVID-19 infection the last 90 days or more\n6. Symptoms compatible with PACS (defined as at least one positive answer to the questionnaire for restriction of daily activities) lasting for more than 2 months\n7. Serum levels of IP-10 more than 250 pg\u002Fml\n8. Presence of ONE of the following two clinical conditions: Condition 1: Impaired Lung Function tests (defined as: DLCOcor \\\u003C76% AND TLC and\u002For FVC lower than 80% of predicted) Condition 2: At least a total radiology score in HRCT more than 20 OR walking of a distance less than 500m in the 6-minute walk test\n\nIf patients meet the criteria for both Conditions 1 and 2, they will be considered for randomization and evaluation for the primary endpoint as in Condition 1.\n\nExclusion Criteria:\n\n1. Age below 18 years\n2. Denial for written informed consent\n3. Any stage IV malignancy\n4. Any primary immunodeficiency\n5. Less than 1,500 neutrophils\u002Fmm3\n6. Known hypersensitivity to anakinra\n7. Known lung fibrosis prior to COVID-19\n8. Medical history of pulmonary hypertension or chronic heart failure\n9. Known chronic obstructive pulmonary disease GOLD stage 3 or 4 prior to COVID-19\n10. Known active tuberculosis (under treatment) or latent tuberculosis (by positive tuberculin test)\n11. Oral or IV intake of corticosteroids at a daily dose equal or greater than 0.4 mg\u002Fkg prednisone for a period greater than the last 15 days.\n12. Any anti-cytokine biological treatment the last one month\n13. Severe hepatic failure defined as Child-Pugh stage of 3\n14. End-stage renal failure necessitating hemofiltration or peritoneal hemodialysis\n15. Pregnancy or lactation. Women of child-bearing potential will be screened by a urine pregnancy test before inclusion in the study\n16. Participation in any other interventional trial",{"count":370,"type":21},182,[214,372],"PHASE3","The PRECISION is a proof-of-concept, phase II randomized clinical trial aiming to evaluate the efficacy and safety of anakinra in patients with Post-Acute COVID Syndrome (PACS) of the pro-inflammatory respiratory phenotype. Improvement is measured by a composite endpoint, namely, the \"Score of PACS progression reversal\"",[27,375,161],"Post-Acute COVID-19",[32,161,375,377,367,364],"Anakinra","2026-01-06",{"date":380,"type":38},"2026-01-08",{"date":382,"type":38},"2023-09-06",{"date":384,"type":21},"2028-03",{"name":386,"class":90},"Hellenic Institute for the Study of Sepsis",24,{"id":389,"slug":390,"hasResults":11,"nctId":391,"briefTitle":392,"officialTitle":393,"acronym":4,"eligibilityCriteria":394,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":395,"targetDuration":4,"studyType":22,"phases":397,"briefSummary":398,"conditions":399,"keywords":400,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":403,"lastUpdatePostDateStruct":404,"startDateStruct":406,"completionDateStruct":408,"leadSponsor":410,"locationsCount":46},"100499755","care-for-veterans-post-covid-19-100499755","NCT05787379","Care for Veterans Post-COVID-19","Leveraging Knowledge of Chronic Multisymptom Illness to Improve Care for Veterans","Inclusion Criteria:\n\n* Part 1 and Part 2, English-speaking VA primary care providers will be included.\n* Part 1, Veterans who self-identify as having Long-COVID will be included.\n* Part 2, Veterans who meet criteria for Long-COVID assessed with modified DePaul Symptom Questionnaire version 2 will be included;\n* Part 2, Veterans must also have a scheduled appointment with one of the participating clinicians within one to six months of the clinician being consented.\n\nExclusion Criteria:\n\n* Part 1 and Part 2, clinicians who have already taken Concordant Care training will be excluded.\n* Part 1, Veterans will be excluded if they are not receiving care in the VA.\n* Part 2, Veterans will be excluded if they were in the Intensive Care Unit (ICU) for COVID-19.",{"count":396,"type":21},348,[73],"The evidence-based Concordant Care approach involves engaging in processes that: 1) validate the patient's experience, 2) develop a shared understanding of the condition, and 3) create a patient-centered, whole health-oriented action plan to manage the condition. This is consistent with published expert opinion that Concordant Care underlies patients' (and clinicians') positive experiences of care for poorly understood conditions. Despite strong evidence supporting this care approach, there are no interventions to train clinicians on practices to provide Concordant Care for Veterans with poorly understood conditions such as Long-COVID. Part 1 of the study will optimize and test if a Concordant Care training improves VA clinicians' engagement in recommended practices to provide Concordant Care (i.e., validate, shared understanding, action plan) for Veterans with Long-COVID. This study will adapt and refine Concordant Care training for Long-COVID. Part 2 of this study will determine if Concordant Care training increases clinicians' engagement in recommended practices to provide Concordant Care and will explore the effectiveness of Concordant Care on care outcomes including satisfaction, adherence to care, \\& disability for Veterans with Long-COVID. Veterans treated by clinicians receiving Concordant Care training will report their clinician more frequently engaged in recommended conversations (i.e., ask about Long-COVID, validate experience with Long-COVID, create a shared understanding and action plan), and Veterans will perceive greater shared understanding of Long-COVID with their clinicians than Veterans treated by clinicians in the control arm.",[27],[401,32,402],"training","post-acute sequelae of COVID infection","2025-12-17",{"date":405,"type":38},"2025-12-24",{"date":407,"type":38},"2025-01-01",{"date":409,"type":21},"2027-11-30",{"name":411,"class":412},"VA Office of Research and Development","FED",{"id":414,"slug":415,"hasResults":11,"nctId":416,"briefTitle":417,"officialTitle":418,"acronym":419,"eligibilityCriteria":420,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":99,"enrollmentInfo":421,"targetDuration":4,"studyType":22,"phases":423,"briefSummary":424,"conditions":425,"keywords":427,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":440,"lastUpdatePostDateStruct":441,"startDateStruct":443,"completionDateStruct":445,"leadSponsor":447,"locationsCount":46},"100608098","impact-d-immune-modulating-and-psychometric-effects-of-accelerated-tms-in-depression-plus-comorbid-post-covid-19-condition-100608098","NCT07197138","IMPACT-D+: Immune-Modulating and Psychometric Effects of Accelerated TMS in Depression Plus Comorbid Post-COVID-19 Condition","Pilot Study on the Effects of Intensified Repetitive Transcranial Magnetic Stimulation on Immunological Blood Parameters in Patients With Depression and Comorbid Post-COVID-19 Condition","IMPACT-D+","Inclusion Criteria:\n\n* Age 18-65 years\n* Capacity to consent (legally competent, written informed consent including data protection)\n* Diagnosis of depression (at least moderate severity, BDI-II ≥ 20), including major depressive episode in bipolar disorder\n* Comorbid diagnosis of Post-COVID-19 condition (WHO definition)\n* Insufficient improvement of depressive symptoms under psychopharmacological treatment\n* Stable psychopharmacological medication for at least 4 weeks prior to start of iTBS\n\nExclusion Criteria:\n\n* Age \\\u003C18 years or \\>65 years\n* Pregnancy, planned pregnancy, or breastfeeding\n* Legal guardianship or cognitive impairment preventing valid informed consent\n* Severe developmental disorder or intellectual disability\n* Acute or chronic substance abuse (alcohol, prescription drugs, or illicit drugs)\n* Current treatment with benzodiazepines or Z-substances\n* Acute suicidality\n* Psychotic symptoms\n* Severe neurological disorder (e.g., major brain injury, neurodegenerative disease)\n* Ongoing treatment with another neurostimulation method (ECT, TMS, VNS)\n* Contraindications to TMS, including: Intracranial metal, implants, shunts, Cochlear implant, pacemaker, implantable defibrillator, History of seizures or epileptiform EEG\n* Severe general medical illness (e.g., anemia requiring transfusion, severe arrhythmias, cardiomyopathy)",{"count":422,"type":21},42,[73],"This is a monocentric, randomized pilot study conducted at the Max Planck Institute of Psychiatry, Munich. The study investigates the effects of two different intermittent theta-burst stimulation (iTBS) schedules on biological and clinical outcomes in patients with depression and comorbid Post-COVID-19 condition (PCC). Participants will be randomized into two arms, both receiving a total of 30 active iTBS sessions applied to the left dorsolateral prefrontal cortex (DLPFC) at 90% resting motor threshold using a PowerMAG 100 ppTMS stimulator:\n\n* Standard Arm: One iTBS session per day, five days per week, over six weeks.\n* Intensified Arm: Six iTBS sessions per day, approximately one-hour apart, over five consecutive days.\n\nThe primary outcomes are changes in immunological blood markers (C-reactive protein \\[CRP\\], tumor necrosis factor \\[TNF\\], interleukin-1β \\[IL-1β\\], interleukin-6 \\[IL-6\\]) and depressive symptomatology measured by Beck Depression Inventory-II (BDI-II) and Montgomery-Asberg Depression Rating Scale (MADRS). Secondary outcomes include fatigue (Fatigue Severity Scale \\[FSS\\], Fatigue Scale for Motor and Cognitive Functions \\[FSMC\\], Post-Exertional Malaise questionnaire \\[PEM\\]), sleep quality (Pittsburgh Sleep Quality Index \\[PSQI\\]), daytime sleepiness (Epworth Sleepiness Scale \\[ESS\\]), functioning (Sheehan Disability Scale \\[SDS\\]), anxiety (Beck Anxiety Inventory \\[BAI\\]) and an exploratory adverse effect screening. Follow-up assessments will be performed three days after treatment completion and again at three months post-intervention to evaluate both short- and medium-term effects. Biospecimen collection will include approximately 141 ml of peripheral blood per participant across three time points (baseline, post-treatment, +3 days). Samples will be analyzed for inflammatory markers and securely stored in the institutional biobank of the Max Planck Institute of Psychiatry in accordance with data protection and ethical guidelines. Safety and tolerability will be continuously monitored, including documentation of adverse events. The results of this pilot study are expected to provide preliminary evidence on whether accelerated iTBS protocols may exert differential effects on neuroinflammatory processes and depressive symptomatology in patients with Post-COVID-19 condition, thereby informing larger controlled clinical trials.",[426,27],"Depressive Disorder",[428,429,430,431,432,433,434,435,436,437,438,439],"Major depressive disorder","Post-COVID-19-condition","neuropsychology","psychometry","Immunemarkers","IL-6","TNF","CRP","repetitive transcranial magnetic stimulation","intermittent theta burst","accelerated rTMS","neuroinflammation","2025-09-26",{"date":442,"type":38},"2025-09-29",{"date":444,"type":38},"2025-09-11",{"date":446,"type":21},"2027-09",{"name":448,"class":90},"Max-Planck-Institute of Psychiatry",{"id":450,"slug":451,"hasResults":11,"nctId":452,"briefTitle":453,"officialTitle":454,"acronym":4,"eligibilityCriteria":455,"healthyVolunteers":237,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":456,"targetDuration":4,"studyType":242,"phases":4,"briefSummary":457,"conditions":458,"keywords":461,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":469,"lastUpdatePostDateStruct":470,"startDateStruct":472,"completionDateStruct":474,"leadSponsor":476,"locationsCount":46},"100457594","imbalances-of-regional-pulmonary-ventilation-in-patients-with-post-acute-covid-19-100457594","NCT05238623","Imbalances of Regional Pulmonary Ventilation in Patients With Post-acute-COVID-19","Imbalances of Regional Pulmonary Ventilation in Patients With Post-acute-COVID-19 Symptoms","Inclusion Criteria:\n\n* all patients undergoing a Chest CT due to suspected post-acute-Covid-19-syndrome\n* \\>18 years\n* informed consent.\n\nExclusion Criteria:\n\n* trauma patients and patients with unstable spinal injuries or fractures\n* patients with an BMI over 50\n* patients with uncontrolled body movements\n* Patients with a pacemaker",{"count":212,"type":21},"Investigation of the correlation of CT-morphological changes of the lung compared to regional ventilation distribution on electrical impedance tomography in patients with post-acute-Covid-19 symptoms.",[459,326,460],"COVID-19 Pneumonia","Electric Impedance",[460,462,463,464,465,466,467,468,78],"CT","Tomography","regional ventilation","post-acute-COVID-19 syndrome","post-COVID-19","EIT","electroimpedance tomography","2025-09-22",{"date":471,"type":38},"2025-09-25",{"date":473,"type":21},"2025-10-01",{"date":475,"type":21},"2027-03-31",{"name":477,"class":90},"Jan-Christoph Lewejohann",{"id":479,"slug":480,"hasResults":11,"nctId":481,"briefTitle":482,"officialTitle":483,"acronym":484,"eligibilityCriteria":485,"healthyVolunteers":237,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":486,"targetDuration":4,"studyType":22,"phases":488,"briefSummary":489,"conditions":490,"keywords":494,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":497,"startDateStruct":499,"completionDateStruct":501,"leadSponsor":503,"locationsCount":46},"100603713","long-covid-19-alleviation-through-learning-mindfulness-study-100603713","NCT07140094","Long-Covid-19 Alleviation Through Learning Mindfulness Study","Long-Covid-19 Alleviation Through Learning Mindfulness Study (LONG-CALM)","LONG-CALM","Inclusion Criteria:\n\n* Age \\> or = 18\n* Willing and able to provide informed consent\n* Access to the internet\n* Self-reported history of SARS-CoV-2 infection\n* Current symptoms attributed to PASC by participant or by participant's medical provider; ongoing symptoms that persisted \\>= 12 weeks after Covid-19 illness\n\nExclusion Criteria:\n\n* Participating in another clinical trial of an intervention for PASC symptoms\n* Engaged in a structured MBI",{"count":487,"type":21},400,[73],"This research is being done to study a mindfulness intervention among people who have symptoms of Post-Acute Sequelae of SARS-CoV-2 infection (PASC), also known as Long COVID. Mindfulness is defined as paying attention to the present moment with non-judgment and acceptance. Here the investigators are studying whether a mindfulness intervention can help reduce stress, reduce Long COVID symptoms, and improve quality of life among people living with Long COVID. The mindfulness intervention is a series of recorded mindfulness sessions, which were created by the study team. People who decide to take part will be randomly assigned to receive the study mindfulness intervention immediately after joining the study or to receive the study mindfulness intervention 8 weeks after joining the study. All participants will continue their usual medical care. Participants will complete online surveys to measure symptoms over time. The study will last 6 months.",[161,491,375,27,492,493],"Long Covid19","Post-Acute COVID-19 Infection","COVID Long-Haul",[495],"Covid","2025-08-21",{"date":498,"type":38},"2025-08-24",{"date":500,"type":38},"2024-05-21",{"date":502,"type":21},"2027-11-21",{"name":504,"class":90},"Columbia University",{"id":506,"slug":507,"hasResults":11,"nctId":508,"briefTitle":509,"officialTitle":510,"acronym":4,"eligibilityCriteria":511,"healthyVolunteers":237,"sex":16,"minAge":17,"maxAge":512,"enrollmentInfo":513,"targetDuration":4,"studyType":22,"phases":514,"briefSummary":515,"conditions":516,"keywords":517,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":524,"lastUpdatePostDateStruct":525,"startDateStruct":527,"completionDateStruct":529,"leadSponsor":531,"locationsCount":46},"100593398","attention-memory-and-quality-of-life-in-post-covid-19-adults-100593398","NCT07005921","Attention, Memory and Quality of Life in Post-COVID-19 Adults","Attention, Memory, Self-reflection and Insight, and Quality of Life in Post-COVID-19 Adults","The inclusion criteria - 1) Be over 18 years old and under 60 years old, 2) Authorize participation in the study through the informed consent form.\n\nThe exclusion criteria - 1) Be under 18 years old and over 60 years old; 2) Discontinue participation in the study, 3) Use psychoactive substances that affect attention and memory, 4) Present physical or cognitive repercussions resulting from other diagnoses prior to or subsequent to COVID-19, 5) Present a history of attention and memory impairment prior to the diagnosis of COVID-19.","60 Years",{"count":186,"type":21},[73],"The pandemic has highlighted social, economic, educational, and political issues that have affected the health and quality of life of millions of Brazilians. Currently, attention and memory impairment remains predominant among the cognitive symptoms of Coronavirus observed in adults. The persistance of the reffered impairment after 12 weeks of COVID-19 is known as cognitive impairment in post-COVID-19 syndrome. Despite studies indicating the negative effects of COVID-19 on attention and memory, there is a gap in the literature regarding its effects on self-reflection and insight. Previous studies highlight the role of self-awareness as an essential cognitive process that aids the criation of a resolution for the social consequences of the ongoing pandemic. Thus, understanding the relationship between self-reflection, insight, memory, and quality of life in adults that presented COVID-19 could reveal how memory loss might affect the ability to evaluate and understand one's own behaviors and quality of life. Moreover, this study could provide a background for future interventions to enhance attention, memory, self-reflection, and insight in this population. In this context, quantitative electroencephalogram neurofeedback training (EEGq-NFT) is a promising non-invasive intervention designed to improve cognition, such as attention and working memory. By modifying electrophysiological patterns in the cerebral cortex. Considering the information presented, the question is what is the relationship between cognitive failures, self-reflection and insight, and quality of life in adults who had COVID-19, and what is the efficacy of EEGq-NFT training in rehabilitating attention and working memory in adults with cognitive impairment due to post-COVID-19 syndrome. This study aims to examine the relationship between cognitive failures, self-reflection, insight, and quality of life in adults post-COVID-19, as well as to assess the efficacy of EEGq-NFT in improving attention and working memory in adults with cognitive impairment due to post-COVID-19 syndrome. Method 1 will employ a survey with cross-sectional design and quantitative data analysis. A total of 385 adults will be recruted. Data will be collected through online forms. Cognitive Failures Questionnaire, Self-Reflection and Insight Scale and WHOQOL-bref scale will be used. In Method 2, a quasi-experimental with quantitative data analysis will be employed. A total of 60 participants will be randomly assigned to an EEGq neurofeedback training group (n = 20), an active control group called SHAM EEGq-neurofeedback (n = 20), and a waiting list control group (n = 20). The theta\u002Fbeta ratio reduction protocol at Cz will be used, with 10 sessions of 30 minutes each. The Psychological Battery of Attention 2 (BPA-2) and Digit Span Test will be employed to measure attention and working memory levels. Statistical analyses will be performed using IBM SPSS version 25 with statistical significance set at p \\\u003C 0.05 for a 95% confidence interval. The research follows all ethical standards for studies involving human subjects and was submitted for review and approval at the Research Ethics Committee. A understanding of memory levels, self-reflection, insight, and quality of life in adults post- COVID-19 is expected as a result of the present study. Additionally, this study expects that EEGq-NFT will be effective in reducing the theta\u002Fbeta ratio, as well as improving attention and working memory in adults with cognitive impairment in post-COVID-19 syndrome.",[27,161,162],[518,519,520,32,521,522,466,523,162],"Attention","Memory","Self-awareness","COVID-19 syndrome","long COVID","Quality of life","2025-06-09",{"date":526,"type":38},"2025-06-12",{"date":528,"type":21},"2025-06-10",{"date":530,"type":21},"2025-12-31",{"name":532,"class":90},"Jade Carvalho Da Silva",{"id":534,"slug":535,"hasResults":11,"nctId":536,"briefTitle":537,"officialTitle":538,"acronym":4,"eligibilityCriteria":539,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":540,"targetDuration":4,"studyType":22,"phases":542,"briefSummary":543,"conditions":544,"keywords":4,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":545,"lastUpdatePostDateStruct":546,"startDateStruct":548,"completionDateStruct":549,"leadSponsor":551,"locationsCount":554},"100561450","phase-2-a-study-of-apabetalone-in-subjects-with-long--covid-100561450","NCT06590324","A Study of Apabetalone in Subjects With Long -COVID","A Phase II, Multi-centre Open Label Study to Assess the Efficacy and Safety of Oral Apabetalone With Background Dapagliflozin in Subjects With Long -COVID-19 (Post-COVID-19 Conditions) and Type 2 Diabetes Mellitus (T2DM)","Inclusion Criteria:\n\n1. Able and willing to provide written (signed and dated) informed consent before participation in the study, and to comply with scheduled visits, treatment plan, and other study-related procedures to complete the study.\n2. Male or female subjects who are ≥ 18 years of age at Screening.\n3. Documented diagnosis of T2DM (one or more of the following criteria must be met):\n\n   1. Documented history of T2DM\n   2. History of taking diabetes medication\n   3. HbA1c ≥6.5% at Screening\n4. Must be taking dapagliflozin as part of their diabetes medication, or, based on the Principal Investigator's judgment and indication, be willing to commence sponsor-provided dapagliflozin 10 mg daily for the duration of the study.\n5. History of Long-COVID symptoms within 3 months from the onset of COVID-19 that have lasted for at least 2 months. Symptoms are listed in Long Covid Symptom Tool (LCST).\n6. A Long Covid Impact Tool (LCIT) score of ≥ 30 at the Screening Visit and at Visit 2 (Day 1)\n7. A negative SARS-CoV-2 test at the Screening Visit and at Visit 2 (Day 1)\n8. Female subjects of childbearing potential and nonsterile male subjects with female partners of childbearing potential must agree to either remain abstinent or use highly effective non-hormonal methods of contraception throughout the study and at least 30 days after the last dose of study drug has been taken. Subjects must adhere to contraceptive use consistent with local regulations regarding the methods of contraception for those participating in clinical studies\n\n   \\-\n\n   Exclusion Criteria:\n9. Subjects with chronic kidney disease (CKD) with an estimated glomerular filtration rate (eGFR) \\\u003C25 mL\u002Fmin\u002F1.73 m2\n10. New York Heart Association Class IV congestive heart failure\n11. Evidence of cirrhosis from liver imaging or biopsy, a history of hepatic encephalopathy, esophageal or gastric varices, active hepatitis, or prior porta-caval shunt procedure; chronic liver diseases such as primary biliary cholangitis, untreated hemochromatosis, and primary sclerosing cholangitis\n12. Subject meets any of the following laboratory criteria at Screening:\n\n    * Alanine transaminase (ALT) or aspartate transaminase (AST) values \\> 1.5x the upper limit of normal (ULN)\n    * Total bilirubin \\>1.5 × ULN.\n    * Evidence of an active hepatitis B virus or hepatitis C virus infection\n    * History of a positive test for human immunodeficiency virus (HIV)\n13. Subjects taking concomitant cytochrome P450 3A4 strong inducers and\u002For strong inhibitors, or corticosteroid use \\>10 mg daily prednisone or equivalent.\n14. Subjects who have received a COVID-19 vaccine or booster in the last 30 days prior to screening (Visit 1).\n15. Subject who have participated in a clinical study and received any investigational medication within the last 30 days prior to screening (Visit 1).\n16. Female subjects who are pregnant, planning to get pregnant, lactating\u002Fbreastfeeding, or has a positive urine pregnancy test at the Screening Visit or prior to enrollment at the Day 1 visit.\n17. Subjects whose safety may be compromised by study participation or are not, in the opinion of the investigator, able or willing to comply with the protocol.",{"count":541,"type":21},200,[214,372],"This is an open label, multicentre, phase II clinical trial that aims to assess the efficacy and safety of oral Apabetalone with background dapagliflozin for up to 12 weeks in T2DM patients with a history of probable or confirmed SARS-CoV-2 infection, with symptoms within 3 months from the onset of COVID-19 that last for at least 2 months and cannot be explained by an alternative diagnosis.",[27],"2025-04-15",{"date":547,"type":38},"2025-04-18",{"date":545,"type":38},{"date":550,"type":21},"2026-03-30",{"name":552,"class":553},"Resverlogix Corp","INDUSTRY",3,{"id":556,"slug":557,"hasResults":11,"nctId":558,"briefTitle":559,"officialTitle":559,"acronym":4,"eligibilityCriteria":560,"healthyVolunteers":237,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":561,"targetDuration":4,"studyType":242,"phases":4,"briefSummary":563,"conditions":564,"keywords":4,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":565,"lastUpdatePostDateStruct":566,"startDateStruct":568,"completionDateStruct":570,"leadSponsor":572,"locationsCount":46},"100502433","incidence-associated-factors-and-burden-of-post-covid-19-condition-in-brazil-100502433","NCT05822193","Incidence, Associated Factors, and Burden of Post COVID-19 Condition in Brazil","Inclusion Criteria:\n\n* Age ≥ 18 years;\n* Brazilian resident;\n* Symptomatica COVID-19 confirmed by reverse transcriptase polymerase chain reaction (RT-PCR) or antigen test for SARS-COV-2 after January 2022, with diagnosis at least 90 days before recruitment.\n\nExclusion Criteria:\n\n* No availability to participate in remote research appointments;\n* Communication difficulty (aphasia, important hearing loss, non-portuguese speaker, severe dementia)\n* Refuse to provide informed consent",{"count":562,"type":21},1694,"This is a national retrospective cohort study with internet-based recruitment which intends to enroll 1,694 adult patients with COVID-19 diagnosis during the SARS-CoV-2 omicron wave in Brazil. Participants with confirmed symptomatic COVID-19 after january 2022 will be evaluated in order to assess incidence, potential risk factors and impact of post COVID-19 condition according to the WHO definition on health-related quality of life and other relevant patient-centered outcomes.",[27],"2025-02-17",{"date":567,"type":38},"2025-02-19",{"date":569,"type":38},"2023-07-21",{"date":571,"type":21},"2025-07-31",{"name":573,"class":90},"Inova Medical",{"id":575,"slug":576,"hasResults":11,"nctId":577,"briefTitle":578,"officialTitle":579,"acronym":580,"eligibilityCriteria":581,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":582,"targetDuration":4,"studyType":242,"phases":4,"briefSummary":583,"conditions":584,"keywords":588,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":596,"lastUpdatePostDateStruct":597,"startDateStruct":599,"completionDateStruct":601,"leadSponsor":602,"locationsCount":360},"100575744","dysfunctional-breathing-in-post-covid-19-condition-100575744","NCT06776263","Dysfunctional Breathing in Post COVID-19 Condition.","Dysfunctional Breathing in Patients With Post COVID-19 Condition","DB-PCC","Inclusion Criteria:\n\n* Patients that state that they have persistent respiratory problems, have 2 or higher on mMRC scale or 23 and over on the Nijmegen scale will be included.\n\nExclusion Criteria:\n\n* Not able to perform the measurements because of cognitive or physical impairments, ongoing intervention of breathing exercises.",{"count":541,"type":21},"The goal of this observational study with a cross-sectional design is to investigate what signs, symptoms and assessment which can describe and explain dysfunctional breathing in patients with post COVID-19 condition. The main question aims to answer which measurements can identify and asses dysfunctional breathing in patients with post COVID-19 condition?\n\nParticipants for this study will be recruited from the ReCov cohort will be evaluated with diffrent measurments and questionnaires.",[585,586,587,27],"Post COVID-19 Condition (PCC)","Dysfunctional Breathing","Breathing Pattern Disorder",[589,590,591,592,593,594,595],"Respiration","Dyspnea","Signs and Symptoms, Respiratory","Hyperventilation","Outcome Assessment, Health Care","Patient Outcome Assessment","Surveys and Questionnaires","2025-02-13",{"date":598,"type":38},"2025-02-14",{"date":600,"type":38},"2025-01-15",{"date":201,"type":21},{"name":603,"class":90},"Karolinska Institutet",{"id":605,"slug":606,"hasResults":11,"nctId":607,"briefTitle":608,"officialTitle":609,"acronym":610,"eligibilityCriteria":611,"healthyVolunteers":237,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":612,"targetDuration":4,"studyType":22,"phases":614,"briefSummary":615,"conditions":616,"keywords":617,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":624,"lastUpdatePostDateStruct":625,"startDateStruct":627,"completionDateStruct":629,"leadSponsor":631,"locationsCount":46},"100535155","acute-cardiovascular-responses-to-a-single-exercise-session-in-patients-with-post-covid-19-syndrome-100535155","NCT06248151","Acute Cardiovascular Responses to a Single Exercise Session in Patients With Post-COVID-19 Syndrome","Acute Cardiovascular Responses to a Single Exercise Session in Patients With Post-Covid-19 Syndrome","ExPostCovid-19","Inclusion Criteria:\n\nPost-Covid Syndrome group:\n\n* have had a positive RT-PCR test for Covid-19;\n* present persistent symptoms of Post Covid 19 syndrome, which have no other health explanation according to the criteria of the World Health Organization (WHO);\n* have the cognitive and physical capacity to perform the exercises; It is\n* low cardiovascular risk classification according to the American College of Sports Medicine criteria.\n\nHealthy group:\n\n* not present persistent symptoms of Post Covid 19 syndrome, which have no other health explanation according to the criteria of the World Health Organization (WHO);\n* have the cognitive and physical capacity to perform the exercises; It is\n* low cardiovascular risk classification according to the American College of Sports Medicine criteria.",{"count":613,"type":21},40,[73],"The objective of the study is to compare the acute cardiorespiratory and perceptual responses to a physical exercise session in those infected by Covid-19 with and without persistent symptoms.",[27],[618,619,620,621,622,623],"Post-Covid 19 Syndrome","Covid-19","fatigue","cardiovascular system","respiratory system","rehabilitation","2024-12-03",{"date":626,"type":38},"2024-12-04",{"date":628,"type":38},"2024-02-15",{"date":630,"type":21},"2025-07-30",{"name":203,"class":90},{"id":633,"slug":634,"hasResults":11,"nctId":635,"briefTitle":636,"officialTitle":636,"acronym":4,"eligibilityCriteria":637,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":638,"enrollmentInfo":639,"targetDuration":4,"studyType":22,"phases":641,"briefSummary":642,"conditions":643,"keywords":644,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":648,"lastUpdatePostDateStruct":649,"startDateStruct":651,"completionDateStruct":653,"leadSponsor":654,"locationsCount":46},"100553954","phase-1-effectiveness-and-safety-of-mesenchymal-stem-cell-therapy-in-long-covid-patients-100553954","NCT06492798","Effectiveness and Safety of Mesenchymal Stem Cell Therapy in Long COVID Patients","Inclusion Criteria:\n\n* Meeting the diagnostic criteria for Long COVID according to WHO.\n* Main symptoms assessed based on CTCAE 5.0.\n* Symptoms evaluated for exclusion reasons of other diseases by relevant specialists.\n* No recent plans for pregnancy (negative pregnancy test within 72 hours for women of childbearing age prior to the start of the trial), and willing to use effective non-pharmaceutical contraceptive measures during the study.\n* Signed informed consent forms and agreements to participate in this clinical trial.\n\nExclusion Criteria:\n\n* Active malignant tumors.\n* Active infections.\n* Abnormal liver or kidney function (ALT, AST \\> 2 times the upper limit of normal; Cr \\> 2 times the upper limit of normal).\n* Women who are pregnant, lactating, or planning to become pregnant during the trial.\n* Participated in other clinical trials within the last 3 months prior to screening.\n* Other reasons deemed inappropriate for participation by the investigator.","70 Years",{"count":640,"type":21},76,[24,214],"The goal of this clinical trial is to evaluate the effectiveness and safety of mesenchymal stem cell therapy in long-COVID patients. The main questions it aims to answer include:\n\n* whether umbilical cord mesenchymal stem cell therapy does benefit long-COVID patients\n* whether umbilical cord mesenchymal stem cell therapy is safe for long-COVID patients.\n\nParticipants' demographics, chief complaints, and vital signs will be collected and recorded. Basic physical examinations, bloodwork routine, biochemical indexes, oxygen saturation (SpO2) levels, 6-minute walk tests, high-resolution computed tomography (HRCT) scan (if necessary) results will be conducted.\n\nParticipants will receive either an intravenous infusion of mesenchymal stem cells, or a placebo for one time. Participants' symptoms will be assessed on Day 28 of the trial. If there is no significant effect, an additional infusion will be given on Days 35-42, and the symptoms will be reassessed 28 days after that.\n\nContinuous nebulized inhalation of UCMSC-derived exosomes will be administered for 5 days twice daily to treatment group, with no treatment given to the control group. Researchers will compare data and information collected from the treatment and control groups to evaluate the safety and efficacy of UCMSC-derived exosomes for the treatment of chronic cough after COVID-19 infection.",[161,27],[27,645,646,647],"Mesenchymal stem cell","Effectiveness","Safety","2024-07-07",{"date":650,"type":38},"2024-07-09",{"date":652,"type":38},"2023-09-01",{"date":146,"type":21},{"name":655,"class":90},"Changhai Hospital",{"id":657,"slug":658,"hasResults":11,"nctId":659,"briefTitle":660,"officialTitle":661,"acronym":4,"eligibilityCriteria":662,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":663,"targetDuration":4,"studyType":22,"phases":665,"briefSummary":666,"conditions":667,"keywords":669,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":676,"lastUpdatePostDateStruct":677,"startDateStruct":679,"completionDateStruct":681,"leadSponsor":682,"locationsCount":46},"100551162","effectiveness-of-non-invasive-neuromodulation-in-patients-with-long-covid-100551162","NCT06456502","Effectiveness of Non-invasive Neuromodulation in Patients With Long-COVID","Effectiveness of Non-invasive Neuromodulation Compared to Placebo on Sleep Quality in Patients With Post-COVID Symptoms: a Randomized Clinical Trial.","Inclusion Criteria:\n\n* Subjects with long COVID or post- acute COVID syndrome\n* With a evolution of at least 6 months after acute SARS-cov-2 infection\n* Whit symptoms present at baseline.\n\nExclusion Criteria:\n\n* Pregnancy.\n* Pacemakers\n* Ulcerations or wounds in the area of electrode application.\n* Decompensated heart disease.\n* Epilepsy and\u002For choreic syndromes.\n* Frequent medication with corticosteroids, hypnotics or supplements such as melatonin, Ashwagandha or phosphatidylserine.\n* Hypersensitivity on hands and feet that influence the use of the gloves and socks from the neuromodulation system.",{"count":664,"type":21},44,[73],"Sleep quality and duration are critical to cognitive, emotional and physical well-being, and poor sleep quality has been associated with an increased risk of cognitive, psychological and cardiometabolic disorders. Several important physiological activities occur during sleep including a reduction in heart rate and blood pressure. In addition, sleep exerts important modulatory effects on hormone release. Previous studies have shown that lack of sleep can generate exaggerated cortisol responses or psychological and physiological stressors. Cortisol has widespread effects throughout the body and brain, affecting mood, arousal, energy, metabolic processes, and immune and inflammatory system functioning. Therefore, disruptions in cortisol secretion during the night can influence a wide variety of processes in our body that may contribute to the perception of poorer sleep quality. In addition, the salivary enzyme α-amylase is considered a biomarker of cognitive, psychosocial, emotional or physical stress. It is important to note that the autonomic nervous system (ANS) regulates several physiological processes, including heart rate, blood pressure, respiration, and digestion. The ANS consists primarily of the sympathetic system and the parasympathetic system. Increased parasympathetic activity is considered to promote health, whereas a dominant or overactive sympathetic branch is considered to be detrimental to health.\n\nA recent study found that both sleep quality and quantity of sleep were associated with resting ANS functioning. They found that poorer sleep quality was associated with greater sympathetic dominance. Research on the sympathetic and parasympathetic branches of the ANS has shown that autonomic imbalances are precursors to disease formation and other health-related risks. Coronavirus disease 2019 (COVID-19), has in many cases involved the presence of long-lasting symptoms several weeks or months after surviving acute infection with the virus, leading to a new disease called long COVID-19 or post-COVID-19 syndrome (PCS). A recent study showed that sleep quality influences the relationship between symptoms associated with sensitization and mood disorders with health-related quality of life in people suffering from long COVID.\n\nNon-invasive neuromodulation directed to ANS may be an option to treat the sleep disorders observed in patients with long COVID.\n\nOBJETIVES:\n\nTherefore, the primary objective of this study is to evaluate the efficacy of a treatment protocol on the ANS by means of non-invasive neuromodulation in aspects related to sleep in long COVID patients compared to placebo. As secondary objectives, we propose to evaluate the efficacy of a treatment protocol on the ANS by non-invasive neuromodulation in aspects related to ANS functioning, psychological variables, fatigue, pain perception and quality of life in patients with long COVID.",[668,326],"Long-COVID",[670,668,671,672,673,674,76,523,675],"Post acute COVID-19 syndrome","Non-invasive neuromodulation","Sleep quality","Depression","Anxiety","Pain","2024-06-12",{"date":678,"type":38},"2024-06-13",{"date":680,"type":21},"2024-06",{"date":201,"type":21},{"name":683,"class":90},"Universidad Rey Juan Carlos"]